TargetBeta
THRB
thyroid hormone receptor beta · also THRB1, THRB2, NR1A2, THR1 · Thyroid hormone receptors
4 programs in company-led studies act on THRB, from 4 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| resmetiromrule | Madrigal Pharmaceuticals | phase 4 | 228 running | – | ChEMBL |
| KYLO-0603 | Sino Biopharmaceutical | phase 2 | 21 running | – | the company's pipeline |
| CG-0416rule | HongKong Curegene Innovation | phase 1 | 11 running | – | the studies' text |
| KPC000154rule | Kunming Pharmaceuticals | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Non-alcoholic Fatty Liver Disease, 2 programs
- Fatty Liver, 1 program
- Fibrosis, 1 program
- Liver Cirrhosis, 1 program
- Liver Diseases, 1 program
- Obesity, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026resmetirom · Madrigal Pharmaceuticals · phase 4 · NCT05500222
- Mar 2027CG-0416 · HongKong Curegene Innovation · phase 1 · NCT07724431
- Aug 15, 2027KYLO-0603 · Sino Biopharmaceutical · phase 2 · NCT07878091
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.